Health technology innovator Photon has secured $16 million in a Series A funding round to overhaul the outdated electronic prescription process. Led by Healthier Capital, with participation from Notation, Flare Capital, and Evidenced, the investment will accelerate Photon's mission to provide patients with real-time price and inventory transparency. This capital infusion aims to resolve critical inefficiencies that create friction for patients, pharmacies, and providers at the crucial moment a prescription is written.
An Infrastructure Problem for a Digital Age
The current e-prescribing infrastructure, largely designed before the widespread adoption of smartphones, fails to meet modern consumer expectations for transparency and choice. When a prescription is written, patients are forced to select a pharmacy on the spot, lacking any insight into out-of-pocket costs, medication availability, or convenient pickup options. This information vacuum creates a frustrating and inefficient experience, resulting in a cascade of administrative burdens like prescription transfers and abandoned fills that ripple across the healthcare ecosystem.
A Platform for Informed Patient Choice
Photon addresses this systemic issue not with a single-point fix but by rebuilding the prescription experience as a comprehensive, end-to-end platform. By integrating directly into the prescriber's workflow, it presents patients with a marketplace showing real-time pricing and stock information from a network of retail and home delivery pharmacies. The platform's engine is powered by artificial intelligence, which synthesizes complex data from pharmacy networks and benefit structures to provide simple, actionable choices for patients.
Fueling Expansion and Health System Integration
The $16 million in new capital will be instrumental in scaling Photon's operations and market presence, specifically by expanding its engineering and commercial teams. A key focus will be deepening integrations with major health systems, transforming the prescription from a simple handoff into a valuable patient engagement touchpoint. This allows health systems to gain real-time visibility into fill activity and better promote their in-house pharmacy services, reducing patient leakage and improving continuity of care.
A Journey of Strategic Evolution
This funding round follows a period of intense strategic focus and resilience for the Brooklyn-based company, which was founded in 2021. After starting in the direct-to-consumer digital health sector, Photon successfully pivoted to serve the complex needs of enterprise clients, a move that solidified its marketplace model. CEO Otto Sipe acknowledged this challenging journey, noting that the team's commitment through difficult periods, including a layoff in 2025, was essential to reaching this milestone.
A Vision for a Transparent Marketplace
Photon's leadership envisions a future where technology ensures patients remain at the center of their healthcare decisions, even as AI plays a larger role. "We're building prescription infrastructure for the AI era," said Sipe, emphasizing a commitment to empowering consumers and fostering a more open, transparent pharmacy marketplace. This vision is shared by investors, with Amir Dan Rubin of Healthier Capital expressing confidence in Photon's ability to modernize the process and deliver an improved experience for all stakeholders.
This Series A funding marks a significant validation of Photon's model, providing the resources to scale its solution and challenge the status quo in medication access. By placing informed patient choice at the core of the prescribing moment, the company is poised to improve medication adherence, reduce administrative waste, and enhance the overall patient experience. As Photon expands its partnerships, its platform has the potential to establish a new, more efficient standard for the entire pharmacy ecosystem.